JPM — JPMorgan Chase & Co.

The market is constructive after the Q2 2026 beat: revenue grew 18% YoY, markets revenue surged 35%, investment banking fees jumped 30%, management raised FY2026 NII guidance to $96.5B ex-markets, and expected net charge-offs were cut to 3.2%. The stock sits near all-time highs with a Buy-leaning analyst consensus, though the immediate tape is not stretched — as of 2026-08-27, RSI was 50.92.

Revenue has drifted higher over the past 12 quarters, from roughly $61.6B in Sep-2023 to $82.5B in Jun-2026. Q2 2026 was a clear acceleration: +18% YoY versus high-single-digit growth in prior quarters, with operating margin expanding to 33.4% from 26.2% a year earlier. TTM EPS rose to $23.33. Part of that Q2 spike reflects a one-time Visa accounting gain and super-strong markets/IB revenue, so the underlying trend is very good but not quite as extreme as the headline print.

At $354.22, JPM is not cheap. TTM P/E is 15.2x versus its 5-year average of 12.0x; P/B is 2.64x and P/S is 3.19x versus a 2.84x average. Forward P/E on next-FY EPS of $24.83 is about 14.3x. The PEG of 0.80 flatters because it embeds a high growth assumption; on a more realistic ~6-7% forward EPS growth rate, the P/E-to-growth ratio is closer to 2x. The deterministic valuation label is 'Rich vs. its own history,' which I agree with.

The market is paying up for consistency and strength rather than discounting a turnaround. If JPM delivers $24.83 of forward EPS and keeps a ~14.5x multiple, fair value is near $360. If the multiple reverts to the historical 12x, the stock would be closer to $298. The current price is not pricing in a collapse, but it is also not pricing in much multiple expansion — future upside has to come from EPS beating estimates, not from the stock getting cheaper.

As of 2026-08-27, RSI was 50.92 — neutral, not overbought or oversold. The stock was -1.0% below its 20-day SMA, +2.2% above its 50-day SMA, and +11.8% above its 200-day SMA. That is an intact intermediate uptrend with short-term consolidation near all-time highs. For an entry, a pullback toward the 50-day SMA or an RSI reset below 40 would offer a more attractive risk/reward than chasing at $354.

• Higher-for-longer rates support net interest income but keep mortgage volumes muted; JPM raised FY2026 NII guidance to $96.5B ex-markets.
• Capital markets are a tailwind right now: Q2 markets revenue +35% and IB fees +30%, but this is a cyclical, volatile source of earnings.
• Consumer credit is holding up better than feared: card spending is up ~5% YTD and expected net charge-offs were cut to 3.2%.
• Regulatory uncertainty: proposed Fed wholesale-funding treatment could cost JPM roughly $13B of expected capital relief.
• AI and technology spending is rising; management raised FY2026 expense guidance to $107.5B, with returns to be scrutinized at the 2027 Investor Day.

• Barclays Global Financial Services Conference in mid-September 2026 for updated Q3 balance-sheet and credit commentary.
• 2027 Investor Day: long-term capital allocation, technology/AI spending returns, and the post-regulatory capital framework.
• Q3 2026 earnings in October, especially whether markets/IB revenue momentum continues.
• Resolution or modification of the proposed Federal Reserve capital rules, which could remove a meaningful overhang.

• Valuation reversion: at 15.2x TTM P/E versus the 12.0x 5-year average, multiple compression would hurt even if EPS holds up.
• Regulatory/capital risk, including the $13B capital-relief dispute and broader Basel-endgame uncertainty.
• Normalization of blowout markets and IB revenues after Q2 2026; the one-time Visa gain is not repeatable.
• Credit deterioration in lower-income consumer or commercial real estate, despite currently benign charge-offs.
• Expense inflation: management raised full-year expense guidance to $107.5B, and tech/AI spending could keep rising.

JPM is a best-in-class bank with record earnings, strong capital, and improving NII/credit trends, but at $354.22 most of that is already in the price. I would not chase the stock here; for long-term investors it is a reasonable core holding, but the better entry is on a pullback toward the 50-day moving average or on a regulatory/market-driven valuation gap. The stock is roughly fairly valued, not a clear bargain.

I applied a justified forward P/E of 14.5x to the next-FY EPS estimate of $24.83, a modest premium to JPM's 5-year average P/E of 12.0x, justified by roughly 16% ROE, a stronger capital-markets franchise, and raised NII guidance, but tempered by regulatory and credit cyclicality. That yields approximately $360.